Clinical trials: Cytokines
Influenza
A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.
This study will evaluate the efficacy and safety of Tamiflu in patients with clinically-diagnosed influenza occurring during an influenza outbreak within the community.
- Trial name
- NCT00436124
- Testing
- oseltamivir [Tamiflu]
- Where
- Italy
- Sponsor
- Hoffmann-La Roche
Coronavirus Infection, Cytokine Storm
Yoga Pranayama Adjuvant to Treat Burden COVID-19
COronaVIrus Disease or Severe Acute Respiratory Syndrome -CoV-2 or COVID-19, mortality occurs mainly from immunological behavior or by suicide after healing .
- Conditions
- Coronavirus Infection, Cytokine Storm, Mental Disorder
- Trial name
- YOCO (NCT04413747)
- Testing
- morning Yoga-based breathing support, pre_lunch Yoga-based breathing support, pre_dinner Yoga-based breathing support
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Health Ricerca e Sviluppo S.R.L.
Soft Tissue Sarcoma
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.
- Trial name
- FLASH (NCT04733183)
- Testing
- Dacarbazine, onfekafusp alfa
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Philogen S.p.A.
Cutaneous Melanoma, Mucosal Melanoma
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
- Trial name
- ARTISTRY-6 (NCT04830124)
- Testing
- Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing
- Where
- 41 sites in United States, Australia and 6 more
- Volunteers
- 173 people
- Sponsor
- Mural Oncology, Inc
Carcinoma, Renal Cell
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive…
- Trial name
- NCT00130897
- Testing
- Sutent
- Where
- 271 sites in United States, Argentina and 48 more
- Sponsor
- Pfizer
Chronic Hepatitis C
Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C
The pathogenesis of chronic hepatitis C (CHC) is associated to severe oxidative stress and non-selective immunological disturbance that leads to necro-inflammation and progression of fibrosis.
- Trial name
- NCT00778843
- Testing
- Viusid
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Non-small Cell Lung Cancer (NSCLC)
F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer
Prospective, open label, non-randomized, phase I/IIb study of F16IL2 in combination with Nivolumab.
- Trial name
- Nivokin (NCT05468294)
- Testing
- F16IL2, Nivolumab, fixed dose
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Philogen S.p.A.
Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder…
- Conditions
- Solid Tumor, Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01134250
- Testing
- F16IL2 in combination with paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Philogen S.p.A.
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Lymphoma, Non-Hodgkin
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00500058
- Testing
- SB-485232, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA
This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects with Rheumatoid…
- Trial name
- NCT00747214
- Testing
- CRx-102, DMARD Therapy
- Volunteers
- 59 people
- Sponsor
- Zalicus
Irritable Bowel Syndrome
A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679
To better understand the way that GW876008 and GSK561679 work on hormone responses in patients with Irritable Bowel Syndrome.
- Trial name
- NCT00511563
- Testing
- GW876008 and GSK561679
- Sponsor
- GlaxoSmithKline
Immunity, Vaccine Reaction
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
The immune system response needs to be forceful but also balanced for a rapid recovery from infection which avoids harmful overreactions.
- Conditions
- Immunity, Vaccine Reaction, Influenza, Covid19
- Trial name
- NCT04798677
- Testing
- ABBC1 Immunoessential
- Where
- Spain
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AB Biotek
Healthy
Non-invasive Sampling Method for Skin Test: Optimization of Sample Collection and Extraction
When absorbent hygiene products-such as panty liners, sanitary pads, incontinence products, or wound care items-are used over extended periods, they can sometimes have negative effects on the skin.
- Trial name
- SPECIMEN (NCT07117747)
- Testing
- Healthy volunteers
- Where
- Sweden
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Essity Hygiene and Health AB
Non-small-cell Lung Cancer (NSCLC) Stage IV
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection
The trial is to evaluate the efficacy and safety of recombinant human Apo-2 ligand in treating patients with advanced retreated non-small cell lung cancer
- Trial name
- NCT03083743
- Testing
- Recombinant human Apo-2 ligand for Injection
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Shanghai Gebaide Biotechnology Co., Ltd.
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Inflammation
An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines
This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete…
- Trial name
- NCT06953518
- Testing
- Qualia Senolytic
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qualia Life Sciences
Malignant Melanoma
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Phase II, non-randomized, multicenter, prospective study designed to test the efficacy and safety of intratumorally administered L19IL2 in patients suffering from metastatic melanoma.
- Trial name
- NCT01253096
- Testing
- Intratumoral injections of L19IL2
- Where
- 3 sites in Austria, Germany
- Volunteers
- 25 people
- Sponsor
- Philogen S.p.A.
Sub-healthy, Hyperlipidemia
The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults
This study investigates whether using Double Filtration Plasmapheresis (DFPP) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood.
- Conditions
- Sub-healthy, Hyperlipidemia, Toxic Metal Ions Accumulation
- Trial name
- NCT06224296
- Testing
- DFPP
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd